BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 14985049)

  • 1. SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled dopamine D1-like receptors: behavioural topography.
    O'Sullivan GJ; Roth BL; Kinsella A; Waddington JL
    Eur J Pharmacol; 2004 Feb; 486(3):273-80. PubMed ID: 14985049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topographical resolution of jaw movements mediated by cyclase- vs. non-cyclase-coupled dopamine D(1)-like receptors: studies with SK&F 83822.
    Fujita S; Lee J; Kiguchi M; Uchida T; Cools AR; Waddington JL; Koshikawa N
    Eur J Pharmacol; 2006 May; 538(1-3):94-100. PubMed ID: 16682023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethological resolution of behavioural topography and D1-like versus D2-like agonist responses in congenic D5 dopamine receptor mutants: identification of D5:D2-like interactions.
    O'Sullivan GJ; Kinsella A; Sibley DR; Tighe O; Croke DT; Waddington JL
    Synapse; 2005 Mar; 55(4):201-11. PubMed ID: 15668951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of behavioural responses to SK&F 83959 in relation to 'D1-like' dopamine receptors not linked to adenylyl cyclase.
    Deveney AM; Waddington JL
    Br J Pharmacol; 1995 Oct; 116(3):2120-6. PubMed ID: 8640354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential involvement of cyclase- versus non-cyclase-coupled D1-like dopamine receptors in orofacial movement topography in mice: studies with SKF 83822.
    Makihara Y; Okuda Y; Kawada C; Matsumoto M; Waddington JL; Koshikawa N; Tomiyama K
    Neurosci Lett; 2007 Mar; 415(1):6-10. PubMed ID: 17234342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethological resolution of behavioral topography and D2-like vs. D1-like agonist responses in congenic D4 dopamine receptor "knockouts": identification of D4:D1-like interactions.
    O'Sullivan GJ; Kinsella A; Grandy DK; Tighe O; Croke DT; Waddington JL
    Synapse; 2006 Feb; 59(2):107-18. PubMed ID: 16320306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice.
    Ralph RJ; Caine SB
    J Pharmacol Exp Ther; 2005 Feb; 312(2):733-41. PubMed ID: 15494551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: novel dopamine D1 receptor antagonists.
    Shah JH; Kline RH; Geter-Douglass B; Izenwasser S; Witkin JM; Newman AH
    J Med Chem; 1996 Aug; 39(17):3423-8. PubMed ID: 8765528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic, ethologically based resolution of spontaneous and D(2)-like vs D(1)-like agonist-induced behavioural topography in mice with congenic D(3) dopamine receptor "knockout".
    McNamara FN; Clifford JJ; Tighe O; Kinsella A; Drago J; Fuchs S; Croke DT; Waddington JL
    Synapse; 2002 Oct; 46(1):19-31. PubMed ID: 12211095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
    Wirtshafter D; Osborn CV
    Eur J Pharmacol; 2005 Dec; 528(1-3):88-94. PubMed ID: 16324697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SK&F 83959 and non-cyclase-coupled dopamine D1-like receptors in jaw movements via dopamine D1-like/D2-like receptor synergism.
    Adachi K; Ikeda H; Hasegawa M; Nakamura S; Waddington JL; Koshikawa N
    Eur J Pharmacol; 1999 Feb; 367(2-3):143-9. PubMed ID: 10078986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prefrontal, accumbal [shell] and ventral striatal mechanisms in jaw movements and non-cyclase-coupled dopamine D1-like receptors.
    Adachi K; Hasegawa M; Fujita S; Lee J; Cools AR; Waddington JL; Koshikawa N
    Eur J Pharmacol; 2003 Jul; 473(1):47-54. PubMed ID: 12877937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists.
    Ryman-Rasmussen JP; Nichols DE; Mailman RB
    Mol Pharmacol; 2005 Oct; 68(4):1039-48. PubMed ID: 15985612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ; Albers LJ; Le H; Creese I
    J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the locomotor stimulant effects of D1-like receptor agonists in mice.
    Desai RI; Terry P; Katz JL
    Pharmacol Biochem Behav; 2005 Aug; 81(4):843-8. PubMed ID: 16000217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Grooming and vacuous chewing induced by SK&F 83959, an agonist of dopamine 'D1-like' receptors that inhibits dopamine-sensitive adenylyl cyclase.
    Downes RP; Waddington JL
    Eur J Pharmacol; 1993 Mar; 234(1):135-6. PubMed ID: 8097163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of dopaminergic systems in opioid receptor desensitization in nucleus accumbens and caudate putamen of rat after chronic morphine treatment.
    Noble F; Cox BM
    J Pharmacol Exp Ther; 1997 Nov; 283(2):557-65. PubMed ID: 9353370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ventral striatal vs. accumbal (shell) mechanisms and non-cyclase-coupled dopamine D(1)-like receptors in jaw movements.
    Hasegawa M; Adachi K; Nakamura S; Sato M; Waddington JL; Koshikawa N
    Eur J Pharmacol; 2001 Jul; 423(2-3):171-8. PubMed ID: 11448482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethologically based resolution of D2-like dopamine receptor agonist-versus antagonist-induced behavioral topography in dopamine- and adenosine 3',5'-monophosphate-regulated phosphoprotein of 32 kDa "knockout" mutants congenic on the C57BL/6 genetic background.
    Nally RE; Kinsella A; Tighe O; Croke DT; Fienberg AA; Greengard P; Waddington JL
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1281-7. PubMed ID: 15140917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine acutely decreases type 3 Na(+)/H(+) exchanger activity in renal OK cells through the activation of protein kinases A and C signalling cascades.
    Gomes P; Soares-da-Silva P
    Eur J Pharmacol; 2004 Mar; 488(1-3):51-9. PubMed ID: 15044035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.